Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024
New outcomes analyses evaluated efficacy and safety of REBYOTA in patients with recurrent C. diff infection in a real-world setting…
-
-
Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024
A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in trials…
-
Ferring to Present New Data Analysis at NASS 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
Parsippany, NJ – September 9, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced they…
-
Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable…
-
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
Parsippany, NJ – June 24, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the…
-
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
1 in 6 people worldwide experience infertility and up to 50% of the time there is a contributing male factor.1,2,3 Stigma,…
-
First Real-World Outcomes Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at DDW 2024
First real-world outcomes analysis evaluated efficacy of REBYOTA in patients with recurrent C. diff infection Ad-hoc analysis evaluated efficacy and…
-
Ferring Announces U.S. FDA Acceptance of Biologics License Application Submission for SI-6603, an Investigational Therapy in Lumbar Disc Herniation
SI-6603 is an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation Lumbar disc herniation can…
-
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3…
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal…